A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05475925

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:29:08.163637+00:00

Published At

2026-04-17T00:00:00+00:00

Record Updated At

2026-04-17

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["LGLL - Large Granular Lymphocytic Leukemia", "Primary Cutaneous Gamma-Delta T-Cell Lymphoma", "Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma", "Hepatosplenic T-cell Lymphoma", "Subcutaneous Panniculitis-Like T-Cell Lymphoma", "Aggressive NK Cell Leukemia", "Systemic EBV1 T-cell Lymphoma, if CD8 Positive", "Hydroa Vacciniforme-Like Lymphoproliferative Disorder", "Extranodal NK/T Cell Lymphoma, Nasal Type", "Enteropathy-Associated T-Cell Lymphoma", "Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma", "Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)", "Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-04-17"

protocolSection.identificationModule.nctId

"NCT05475925"

protocolSection.identificationModule.officialTitle

"A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• LGLL - Large Granular Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
• Primary Cutaneous Gamma-Delta T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Hepatosplenic T-cell Lymphoma (protocolSection.conditionsModule.conditions)
• Subcutaneous Panniculitis-Like T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Aggressive NK Cell Leukemia (protocolSection.conditionsModule.conditions)
• Systemic EBV1 T-cell Lymphoma, if CD8 Positive (protocolSection.conditionsModule.conditions)
• Hydroa Vacciniforme-Like Lymphoproliferative Disorder (protocolSection.conditionsModule.conditions)
• Extranodal NK/T Cell Lymphoma, Nasal Type (protocolSection.conditionsModule.conditions)
• Enteropathy-Associated T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker) (protocolSection.conditionsModule.conditions)
• Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.